Post

Regeneron and Mammoth team up to develop gene editing therapies

Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing …

AstraZeneca posts $2.18bn profit after tax in Q1 2024

AstraZeneca has reported profit after tax of $2.18bn for the first quarter (Q1) of 2024, a notable rise from $1.80bn …

Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy

Senator Bernie Sanders has targeted the high drug prices of Novo Nordisk’s Ozempic and Wegovy, revealing that the Senate Committee …

Cidara buys back rights to flu therapy from J&J for $85m

Cidara Therapeutics has entered into a definitive agreement with Johnson & Johnson (J&) to buy back the rights to its …

Inflation Reduction Act to have knock on effect on R&D, say biotech experts 

Discussions surrounding the Inflation Reduction Act (IRA) are heating up as the 2026 effect date gets closer. Speakers at the …